Kamran Alam Net Worth

The estimated Net Worth of Kamran Alam is at least $7.71 Million dollars as of 24 August 2023. Mr. Alam owns over 33,000 units of Rocket Pharmaceuticals Inc stock worth over $4,910,539 and over the last 5 years he sold RCKT stock worth over $751,565. In addition, he makes $2,051,460 as Senior Vice President - Finance and Principal Financial Officer at Rocket Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Alam RCKT stock SEC Form 4 insiders trading

Kamran has made over 4 trades of the Rocket Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 33,000 units of RCKT stock worth $76,890 on 24 August 2023.

The largest trade he's ever made was selling 33,000 units of Rocket Pharmaceuticals Inc stock on 24 August 2023 worth over $76,890. On average, Kamran trades about 6,533 units every 49 days since 2019. As of 24 August 2023 he still owns at least 258,042 units of Rocket Pharmaceuticals Inc stock.

You can see the complete history of Mr. Alam stock trades at the bottom of the page.

Kamran Alam biography

Kamran Alam CPA serves as Senior Vice President - Finance, Principal Financial Officer of the Company. Prior to joining Rocket, Mr. Alam was Vice President, Finance at AveXis, Inc. from April 2016 to October 2019. From March 2013 to April 2016, he held positions of increasing responsibility at Aptinyx, where at the time of his departure he was a Senior Director, Finance and Accounting. Previously, he was a Director of Finance at Naurex, and earlier in his career, Mr. Alam held various finance and project management roles with increasing responsibility at Ovation Pharmaceuticals, Lundbeck and Fresenius Kabi. Mr. Alam is a Certified Public Accountant, and received his Bachelor of Business Administration degree from the Ross School of Business at University of Michigan and an M.B.A. in Finance from the Kelley School of Business at Indiana University.

What is the salary of Kamran Alam?

As the Senior Vice President - Finance and Principal Financial Officer of Rocket Pharmaceuticals Inc, the total compensation of Kamran Alam at Rocket Pharmaceuticals Inc is $2,051,460. There are 2 executives at Rocket Pharmaceuticals Inc getting paid more, with Gaurav Shah having the highest compensation of $3,883,650.

How old is Kamran Alam?

Kamran Alam is 41, he's been the Senior Vice President - Finance and Principal Financial Officer of Rocket Pharmaceuticals Inc since 2019. There are 16 older and no younger executives at Rocket Pharmaceuticals Inc. The oldest executive at Rocket Pharmaceuticals Inc is Pedro Granadillo, 73, who is the Independent Director.

What's Kamran Alam's mailing address?

Kamran's mailing address filed with the SEC is C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, STE 1430, DALLAS, TX, 75247.

Insiders trading at Rocket Pharmaceuticals Inc

Over the last 7 years, insiders at Rocket Pharmaceuticals Inc have traded over $45,364,690 worth of Rocket Pharmaceuticals Inc stock and bought 2,407,332 units worth $48,979,646 . The most active insiders traders include Investments, Lpwong Roderic..., Mikael Dolsten, and Investments, Lpwong Roderic.... On average, Rocket Pharmaceuticals Inc executives and independent directors trade stock every 30 days with the average trade being worth of $1,269,815. The most recent stock trade was executed by John Militello on 16 August 2024, trading 1,064 units of RCKT stock currently worth $19,684.

What does Rocket Pharmaceuticals Inc do?

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.

Complete history of Mr. Alam stock trades at Rocket Pharmaceuticals Inc and Taysha Gene Therapies

Rocket Pharmaceuticals Inc executives and stock owners

Rocket Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Gaurav Shah,
  President, Chief Executive Officer, Director
• Kinnari Patel,
  Chief Operating Officer and Head of Development
• Kamran Alam,
  Senior Vice President - Finance, Principal Financial Officer
• Jonathan Schwartz,
  Chief Medical Officer
• Dr. Gaurav D. Shah,
  CEO & Director
• Kinnari Patel M.B.A., Pharm.D., PharmD, MBA,
  Pres, COO & Head of Devel.
• Jonathan Schwartz,
  Chief Medical Officer & Sr. VP of Clinical Devel.
• John C. Militello CPA, CPA,
  VP, Sr. Controller & Principal Accounting Officer
• Roderick Wong,
  Chairman of the Board
• Pedro Granadillo,
  Independent Director
• Carsten Boess,
  Independent Director
• Naveen Yalamanchi,
  Independent Director
• Gotham Makker,
  Independent Director
• David Southwell,
  Director
• Elisabeth Bjork,
  Independent Director
• John Militello,
  Principal Accounting Officer and Senior Controller
• Dr. Gayatri R. Rao J.D., M.D.,
  Chief Devel. Officer of LVV & Sr. VP
• Isabel Carmona J.D.,
  Sr. VP & Chief HR Officer
• Kevin Giordano,
  Director of Corp. Communications
• Martin L. Wilson,
  Gen. Counsel, Chief Compliance Officer & Sr. VP
• Mayur Kasetty,
  Bus. Devel. & Operations and Investor Relations Lead
• Carlos Garcia-Parada M.B.A.,
  Chief Financial Officer
• Investments, Lpwong Roderic...,
  
• Mark Andrew White,
  See Remarks
• Investments, Lpwong Roderic...,
  
• Roderickrtw Investments, Lp...,
  
• Keith Woods,
  
• Fady Ibraham Malik,
  
• Carlos Garcia Parada,
  Chief Financial Officer
• Martin Wilson,
  General Counsel
• Mikael Dolsten,
  
• Aaron Ondrey,
  Chief Financial Officer